Hjem › Eggstokkreft › Alabama › Birmingham
Kliniske studier for Eggstokkreft i Birmingham, AL
23 studier for Eggstokkreft søker deltakere på steder i og rundt Birmingham (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RekruttererFase 2
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
RekruttererFase 2
- UAB O'Neal Comprehensive Cancer Center - The Kirklin Clinic of UAB Hospital, Birmingham
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RekruttererFase 2
- University of Alabama at Birmingham (UAB) Hospital /ID# 274793, Birmingham
DESTINY-PANTUMOUR04
RekruttererObservasjonsstudie
- Research Site, Birmingham
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
RekruttererFase 1/2
- University of Alabama_6th Ave, Birmingham
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
RekruttererFase 3
- University of Alabama at Birmingham, Birmingham
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)
RekruttererFase 3
- University of Alabama - Birmingham ( Site 0058), Birmingham
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
RekruttererObservasjonsstudie
- University of Alabama at Birmingham, Birmingham
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer
RekruttererFase 2
- The University of Alabama at Birmingham, Birmingham
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
RekruttererFase 1/2
- The University of Alabama, Birmingham
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekruttererFase 1
- University of Alabama Birmingham, Birmingham
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RekruttererFase 3
- University of Alabama at Birmingham ( Site 0006), Birmingham
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
RekruttererFase 1/2
- Children's Hospital of Alabama, Birmingham
Study of NTB-928 in R/R OC
RekruttererFase 1
- The University of Alabama, Birmingham
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Rekrutterer
- University of Alabama at Birmingham Cancer Center, Birmingham
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RekruttererFase 3
- University of Alabama at Birmingham Cancer Center, Birmingham
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RekruttererFase 1/2
- University of Alabama at Birmingham, Birmingham
The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- University of Alabama at Birmingham, Birmingham
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RekruttererFase 2
- 004, Birmingham
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RekruttererFase 2
- University of Alabama at Birmingham Womens & Infants Center, Birmingham
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro
RekruttererFase 2
- O'Neal Comprehensive Cancer Center at UAB, Birmingham
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Rekrutterer
- University of Alabama at Birmingham, Birmingham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RekruttererObservasjonsstudie
- Massive Bio SYNERGY-AI site, Birmingham
Eggstokkreft-studier i andre byer
- Houston, TX89 studier
- New York City, NY69 studier
- Boston, MA61 studier
- Los Angeles, CA50 studier
- Nashville, TN49 studier
- Arlington, VA46 studier
- Philadelphia, PA44 studier
- Columbus, OH39 studier
- St. Louis, MO38 studier
- Chicago, IL36 studier
- San Antonio, TX31 studier
- Cleveland, OH30 studier
Andre studier i Birmingham
- Kreft (alle typer)31 studier
- Brystkreft24 studier
- Fedme23 studier
- Ikke-småcellet lungekreft22 studier
- Akut myelogen leukemi21 studier
- Multipelt myelom18 studier
- KOLS17 studier
- Kardiovaskulær sykdom17 studier
- Type 2-diabetes16 studier
- Endometriekreft16 studier
- Overvekt16 studier
- Cystisk fibrose16 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.